NTLA
When one whale blinks
Intellia Therapeutics is back in the feed, this time because Sumitomo Mitsui Trust Group Inc. reportedly trimmed its position to about $19.71 million. That’s not exactly a “sell everything and run for the hills” headline, but when a big institution nudges the exit door, traders tend to notice.
The real story: biotech math is still ugly
The company’s latest quarter beat expectations on the top and bottom lines — EPS came in at ($0.83) versus ($0.99) expected, and revenue jumped 78% year over year to $23.02 million. Nice. But Intellia is still firmly in the biotech pain cave: it remains unprofitable, with a deeply negative net margin and a full-year EPS forecast around -5.07.
Analysts are basically arguing in public
The Street isn’t exactly reading from the same script here. Consensus still sits at Hold with an average target around $19.59, but a few firms have turned more upbeat lately — including HC Wainwright, which lifted its target to $30 and kept a Buy rating. Meanwhile, Bank of America held the line at Neutral. So yeah, the analyst crowd is split between “promising future” and “show me the cash flow.”
What you should care about
For NTLA, the key question isn’t whether one institution trimmed its stake. It’s whether the company can keep growing revenue fast enough to justify all the optimism while still burning cash like a startup with a lab coat. If clinical progress and funding discipline stay on track, the stock has room to run. If not, every bullish target just becomes a very expensive opinion.
Big picture: the market is still treating Intellia like a science project with blockbuster potential — but investors are going to demand more than good vibes and revenue growth before they fully buy in.